Resources
Resources
Resources
Looking for Angel Investor to start a Vaccine Fill & Finish facility in Africa
Posted by: Ramkumar Rajagopalan on 7/13/2016 10:20:38 AM
Funding Needed:
Above $1mil
Category:
Biotechnology
Location :
Nigeria
Viewed : 456 times
Favorited : 0 times
Share
Description:
The fastest growing segment in the biopharmaceutical industry is human vaccines. The demand for vaccines is expanding rapidly because of the steady growth in government immunization programs on a global scale. Procurements of various vaccines by organizations like WHO, UNICEF and GAVI have increased dramatically since 2000. As per latest report the vaccine industry market size is around $ 40 billion and growth rate is very high comparable to the pharmaceutical products. The overwhelming majority of vaccines in Africa are imported. The purchase of most vaccines in Africa is subsidized through donor organizations. The remaining vaccines in Africa are sold through self-pay segment of the market. Main donors are UNICEF and GAVI, we understood there is an huge opportunity in Africa if we build an Vaccine formulation fill & finish facility . The idea of going for the Fill & Finish facility ( Phase 1 ) is to save the time to build the facility and produce the final products, reduce the operational cost and less statutory approval from the regulatory authorities. Simultaneously planning to build a Research & Development facility inside the plant to mainly focus to develop an Africa specific disease vaccine development, also planning to apply for the WHO Pre-Qualification for the vaccines to supply across the world. As an individual i have an very good experience in Vaccine industry ( especially into vaccine business development internationally ) and i have very good back up with technically qualified people who dedicated nearly 25 years into vaccine development. Currently we are looking for the investor for this project and the people who are interested can reach me.
Respond
You must be a member to respond to this post. If you are a member , please login to respond.